Search tips
Search criteria 


Logo of jrsocmedLink to Publisher's site
J R Soc Med. 1992 March; 85(3): 136–138.
PMCID: PMC1294812

Responses of liver metastases to radiotherapy and razoxane.


Twenty-five patients with liver metastases, chiefly due to colorectal cancer, were given a loading dose of razoxane for 3 days before 5 consecutive days of radiotherapy to the whole liver. Patients also took razoxane during the radiotherapy and then for one month afterwards. Liver tumour volume was measured on CT scans using the ELSCINT 3D soft tissue imaging programme just before and 4 weeks after the end of radiotherapy treatment. Twelve of the 25 patients had tumour volume reductions of more than 50%. The overall major response rate therefore is 12/25 (48%). In two of the major responders the liver metastases were due to recurrent stomach cancer. In addition to the 12 responders, four patients had a reduction of more than 20% but less than 50%, thus giving an overall response rate of 16/25 (64%). These results can form the basis of a formal, randomized, controlled clinical trial of radiotherapy alone (or any other treatment) compared with radiotherapy and razoxane in the difficult and life threatening condition presented by liver metastases.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (464K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Taylor IW, Bleehen NM. Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line. Br J Cancer. 1977 May;35(5):587–594. [PMC free article] [PubMed]
  • Hellmann K, Murkin GE. Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors. Cancer. 1974 Oct;34(4):1033–1039. [PubMed]
  • Ryall RD, Hanham IW, Newton KA, Hellmann K, Brinkley DM, Hjertaas OK. Combined treatment of soft tissue and osteosarcomas by radiation and ICRF 159. Cancer. 1974 Oct;34(4):1040–1045. [PubMed]
  • Rhomberg WU. Radiotherapy combined with ICRF 159 (NSC 129943). Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):121–126. [PubMed]
  • Rhomberg W, Eiter H. Radioonkologische Behandlungschancen beim Lokalrezidiv des Rektumkarzinoms. Ein interdisziplinärer Vergleich. Wien Med Wochenschr. 1990 Apr 30;140(8):206–211. [PubMed]
  • Bakowski MT, Macdonald E, Mould RF, Cawte P, Sloggem J, Barrett A, Dalley V, Newton KA, Westbury G, James SE, et al. Double blind controlled clinical trial of radiation plus razoxane (ICRF 159) versus radiation plus placebo in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys. 1978 Jan-Feb;4(1-2):115–119. [PubMed]
  • Belloni C, Mangioni C, Bortolozzi G, Carinelli S, D'Incalci M, Maggioni A, Morasca L. ICRF 159 plus radiation versus radiation therapy alone in cervical carcinoma. A double-blind study. Oncology. 1983;40(3):181–185. [PubMed]
  • Sharpe HB, Field EO, Hellmann K. Mode of action of the cytostatic agent "ICRF 159". Nature. 1970 May 9;226(5245):524–526. [PubMed]
  • Leibel SA, Pajak TF, Massullo V, Order SE, Komaki RU, Chang CH, Wasserman TH, Phillips TL, Lipshutz J, Durbin LM. A comparison of misonidazole sensitized radiation therapy to radiation therapy alone for the palliation of hepatic metastases: results of a Radiation Therapy Oncology Group randomized prospective trial. Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1057–1064. [PubMed]
  • Kinsella TJ. The role of radiation therapy alone and combined with infusion chemotherapy for treating liver metastases. Semin Oncol. 1983 Jun;10(2):215–222. [PubMed]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press